Drugs / GSK2340273A
last change Aug 2012 re-read 2 minutes ago

GSK2340273A

Vaccine

Developed for
influenza
Investigated by
GlaxoSmithKline

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01236040 Nov 2010 → Sep 2011 influenza GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT01059617 Feb 2010 → Jan 2011 influenza GlaxoSmithKline Completed No outcome recorded
Phase 24 trials
Phase 2 NCT01035749 Feb → Sep 2010 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00976820 Oct 2009 → Mar 2011 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00985088 Oct → Nov 2009 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00985673 Oct → Dec 2009 influenza GlaxoSmithKline Completed No outcome recorded
Phase 32 trials
Phase 3 NCT01051661 Feb 2010 → Aug 2011 influenza GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00979602 Nov 2009 → Jan 2011 influenza GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as GSK2340273A ClinicalTrials.gov intervention name — accepted as the source's own label NCT01236040
7

NCT01059617

NCT01035749

NCT01051661

NCT00976820

NCT00985673

NCT00985088

NCT00979602

Modality Vaccine “GSK2340273A-formulation 1 (F1) vaccineNCT00976820
Route Intramuscular “one or two intramuscular injections” NCT00985088